CTRI/2021/04/033045尚未招募未知
Evaluation of the clinical efficacy of Thymoquinone gel as an Anti plaque and Anti gingivitis agent: A blinded randomized study.
Saima Yunus Khan0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)12- 18 years of age
- •2)28 permanent teeth in occlusion
- •3)Be in a good general health
- •4)Given written informed consent
- •5)Has not received any periodontal therapy within the preceding 6 months.
- •6)Diagnosed with mild to moderate type of gingivitis on score
排除标准
- •1)All those not willing to participate.
- •2)Any underlying systemic disease.
- •3)On Orthodontic treatment â?? fixed or removable
- •4)Not willing to comply with the recall visits
- •5)Smokers.
- •6)On any regular medication which could decrease the salivary flow.
研究者
相似试验
招募中
2 期
Evaluation of Efficacy and Safety of Thymoquinone compared to Best supportive care in Patients with COVID-19CTRI/2020/05/025167Intas Pharmaceuticals Ltd
尚未招募
3 期
The effect of thymoquinone on infantile spasmIRCT20200131046317N2Mashhad University of Medical Sciences20
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyEUCTR2020-002100-39-FRPTC THERAPEUTICS, INC.80
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyGenetically determined mitochondrial disease and associated refractory epilepsyMedDRA version: 20.0Level: LLTClassification code 10077953Term: Refractory epilepsySystem Organ Class: 100000004852MedDRA version: 20.0Level: HLTClassification code 10052637Term: Genetic mitochondrial abnormalities NECSystem Organ Class: 100000004850EUCTR2020-002100-39-PLPTC THERAPEUTICS, INC.80
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyGenetically determined mitochondrial disease and associated refractory epilepsyEUCTR2020-002100-39-SEPTC THERAPEUTICS, INC.88